Please assess the completion status of the following clinical trial:

Trial Title: ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed melanoma~  * Inoperable locally recurrent or metastatic disease~* Measurable disease~  * No lytic or blastic bone metastasis as only evidence of metastasis~ * Prior radiotherapy to a target lesion allowed provided there has been clear progression of disease since completion of radiotherapy~* No active brain metastasis, including leptomeningeal involvement~  * Prior brain metastasis allowed provided the disease is in complete remission for at least 1 month after therapy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* More than 12 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL~Hepatic~* AST and ALT ≤ 2.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis)~* Bilirubin ≤ 1.5 mg/dL~Renal~* Creatinine ≤ 1.5 mg/dL~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception 1 month before and during study participation~* No pre-existing peripheral neuropathy ≥ grade 2~* No prior allergy or hypersensitivity to study drug~* No concurrent clinically significant illness~* No other concurrent active malignancy~* No serious medical risk factors involving any of the major organ systems that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Recovered from prior chemotherapy~* More than 4 weeks since prior cytotoxic chemotherapy~* At least 3 weeks since prior anthracyclines~* No concurrent taxane or anthracyclines~* No concurrent doxorubicin~Endocrine therapy~* No concurrent steroids except as needed for hypersensitivity to study drug~Radiotherapy~* See Disease Characteristics~* Concurrent radiotherapy to a symptomatic non-target lesion (including recurrent or new brain metastases that develop during study participation) allowed~Surgery~* Not specified~Other~* More than 4 weeks since prior investigational drugs and recovered~* No other concurrent anticancer therapy~* No concurrent participation in another clinical study~* No other concurrent investigational therapies~* No concurrent ritonavir, saquinavir, indinavir, or nelfinavir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).